Status:
COMPLETED
Psoas Compartment Block (PCB) Versus L.A Infiltration and Remifentanil Infusion During EVAR
Lead Sponsor:
Dr. Erfan and Bagedo General Hospital
Conditions:
Analgesic Adverse Reaction
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Endovascular aneurysm repair (EVAR) was introduced in 1990 for the first time as a minimally invasive procedure instead of the conventional open surgical repair, with the aim to decrease morbidity and...
Detailed Description
Anatomical, imaging and clinical studies suggest that psoas compartment block (PCB) which was done at L2-L3 level has a high possibility to include L1-L2 roots, and thus can be suitable for inguinal s...
Eligibility Criteria
Inclusion
- All elective patients presenting with aortoiliac aneurysm who will undergo percutaneous EVAR.
Exclusion
- Exclusion criteria included the presence of an aneurysm of the common femoral artery or severe atherosclerotic disease with total occlusion, emergency EVAR, uncooperative patient, patient on anticoagulation therapy, cerebrovascular disease, poorly controlled hypertension (systolic arterial pressure ≥160 mmHg), poorly controlled diabetes mellitus (random blood glucose ≥200 mg/dL) and renal insufficiency (creatinine \>1.5 mg/dL).
Key Trial Info
Start Date :
February 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03443518
Start Date
February 6 2018
End Date
December 10 2018
Last Update
February 18 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
DR Erfan hospital
Jeddah, Saudi Arabia, 0000
2
Erfan hospital
Jeddah, Saudi Arabia